Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: Moderna 0.145, AstraZeneca 15.384.
Moderna vs AstraZeneca Net Worth and Market Cap
Moderna (MRNA) and AstraZeneca (AZN) are peers in Vaccines. Moderna reported revenue of $145M as of Q2 2026, compared with $15.4B for AstraZeneca. AstraZeneca leads on revenue.
Moderna's gross margin is 35.9% versus 83.6% for AstraZeneca. Moderna's net margin is -539.3% versus 16.3% for AstraZeneca.
Key differences
- Revenue growth from Q2 2025 to Q2 2026: AstraZeneca +6.4%, Moderna +2.1%.
- AstraZeneca made an operating profit in its latest quarter (20.6% margin); Moderna made an operating loss (-562.1%).
- Moderna's KPIs on Sterling include Cash, Cash Equivalents and Investments (Quarterly) and Net Product Sales vs Deferred Revenue (Quarterly).
- AstraZeneca's KPIs on Sterling include Alliance Revenue by Partnered Medicine (Quarterly) and AZD5004 + AZD6234 Trial Timeline: Oral GLP-1 + Oral Amylin.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Moderna, AstraZeneca.| Metric | Moderna | AstraZeneca |
|---|---|---|
| Market Cap | - | - |
| Revenue | $145.00M | $15.38B |
| Cost of Revenue | $93.00M | $2.52B |
| Gross Profit | $52.00M | $12.86B |
| Operating Income | $-815.00M | $3.16B |
| Net Income | $-782.00M | $2.51B |
| R&D Expense | $651.00M | $4.05B |
| Earnings Per Share | -$1.96 | $1.59 |
| Gross Margin | 35.9% | 83.6% |
| Operating Margin | -562.1% | 20.6% |
| Net Profit Margin | -539.3% | 16.3% |
| Free Cash Flow | $-563.00M | $2.13B |
| Cumulative Free Cash Flow | $7.37B | $121.22B |
| Operating Cash Flow | $-526.00M | $2.89B |
| Cash & Equivalents | $1.72B | $4.89B |